|
|
|
Volumn 32, Issue 1, 2013, Pages 65-77
|
|
The off-label use of medication: the latest on the Avastin - Lucentis debacle.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANGIOGENESIS INHIBITOR;
BEVACIZUMAB;
MONOCLONAL ANTIBODY;
RANIBIZUMAB;
ARTICLE;
CLINICAL TRIAL (TOPIC);
ETHICS;
EUROPEAN UNION;
HUMAN;
LEGAL ASPECT;
OFF LABEL DRUG USE;
RETINA MACULA DEGENERATION;
ANGIOGENESIS INHIBITORS;
ANTIBODIES, MONOCLONAL, HUMANIZED;
CLINICAL TRIALS AS TOPIC;
EUROPEAN UNION;
HUMANS;
MACULAR DEGENERATION;
OFF-LABEL USE;
|
|
EID: 84880148298
PISSN: 07231393
EISSN: None
Source Type: None
DOI: None Document Type: Article |
|
Times cited : (13)
|
|
References (0)
|
